HUP0303876A3 - Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv - Google Patents

Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv

Info

Publication number
HUP0303876A3
HUP0303876A3 HU0303876A HUP0303876A HUP0303876A3 HU P0303876 A3 HUP0303876 A3 HU P0303876A3 HU 0303876 A HU0303876 A HU 0303876A HU P0303876 A HUP0303876 A HU P0303876A HU P0303876 A3 HUP0303876 A3 HU P0303876A3
Authority
HU
Hungary
Prior art keywords
tiazolidine
piperidine
diabetes
inhibitors
preparation
Prior art date
Application number
HU0303876A
Other languages
English (en)
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HUP0303876A2 publication Critical patent/HUP0303876A2/hu
Publication of HUP0303876A3 publication Critical patent/HUP0303876A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
HU0303876A 2001-04-11 2002-04-10 Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv HUP0303876A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0109146.1A GB0109146D0 (en) 2001-04-11 2001-04-11 Treatment of type 2 diabetes
PCT/GB2002/001674 WO2002083109A1 (en) 2001-04-11 2002-04-10 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv

Publications (2)

Publication Number Publication Date
HUP0303876A2 HUP0303876A2 (hu) 2004-03-01
HUP0303876A3 true HUP0303876A3 (en) 2005-06-28

Family

ID=9912727

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303876A HUP0303876A3 (en) 2001-04-11 2002-04-10 Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv

Country Status (22)

Country Link
US (1) US20040209891A1 (hu)
EP (1) EP1377278B1 (hu)
JP (1) JP2004525179A (hu)
KR (1) KR20040025915A (hu)
CN (1) CN1248683C (hu)
AT (1) ATE344029T1 (hu)
AU (1) AU2002244860B2 (hu)
CA (1) CA2443229A1 (hu)
CZ (1) CZ20032927A3 (hu)
DE (1) DE60215787T2 (hu)
GB (1) GB0109146D0 (hu)
HK (1) HK1059213A1 (hu)
HU (1) HUP0303876A3 (hu)
IL (1) IL157821A0 (hu)
MX (1) MXPA03009224A (hu)
NO (1) NO20034549D0 (hu)
NZ (1) NZ528172A (hu)
PL (1) PL366633A1 (hu)
RU (1) RU2328283C2 (hu)
UA (1) UA76452C2 (hu)
WO (1) WO2002083109A1 (hu)
ZA (1) ZA200307156B (hu)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60222667T2 (de) 2001-06-27 2008-07-17 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
GB0125445D0 (en) * 2001-10-23 2001-12-12 Ferring Bv Protease Inhibitors
AU2002952946A0 (en) * 2002-11-27 2002-12-12 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
DE602004010206T2 (de) 2003-08-13 2008-10-09 Takeda Pharmaceutical Co. Ltd. Dipeptidyl Peptidase Inhibitoren.
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
KR20150028829A (ko) 2003-11-17 2015-03-16 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
US20070149451A1 (en) * 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
BRPI0507007A (pt) 2004-01-20 2007-06-05 Novartis Ag formulação e processo de compressão direta
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2559302C (en) 2004-03-15 2012-06-19 Takeda Pharmaceutical Company Limited 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EP1794120B1 (en) 2004-07-23 2012-04-11 Nuada, LLC Peptidase inhibitors
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
CN101277949A (zh) 2005-04-22 2008-10-01 阿兰托斯制药控股公司 二肽基肽酶-ⅳ抑制剂
AU2006278039B2 (en) * 2005-08-11 2010-10-21 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a DPP-lV inhibitor
PT1942898E (pt) 2005-09-14 2011-12-20 Takeda Pharmaceutical Inibidores da dipeptidilpeptidase para o tratamento da diabetes
JP5122462B2 (ja) 2005-09-16 2013-01-16 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
FR2938999B1 (fr) * 2008-11-24 2011-07-01 Oreal Procede de preparation d'un parfum au sein d'un systeme comportant une pluralite de terminaux interactifs de formulation de parfums et un serveur agence pour echanger des donnees avec la pluralite de terminaux
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
SG11201909046XA (en) 2017-04-03 2019-10-30 Coherus Biosciences Inc PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
DE19823831A1 (de) * 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
EP1189629B1 (en) * 1999-02-10 2010-09-29 Curis, Inc. Peptide yy (pyy) for treating glucose metabolic disorders
GB9906714D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
US6107317A (en) * 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2001034594A1 (en) * 1999-11-12 2001-05-17 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
JP2003528135A (ja) * 2000-03-31 2003-09-24 プロバイオドラッグ アーゲー 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment

Also Published As

Publication number Publication date
IL157821A0 (en) 2004-03-28
MXPA03009224A (es) 2004-01-29
US20040209891A1 (en) 2004-10-21
DE60215787T2 (de) 2007-08-30
EP1377278B1 (en) 2006-11-02
KR20040025915A (ko) 2004-03-26
NO20034549L (no) 2003-10-09
GB0109146D0 (en) 2001-05-30
HUP0303876A2 (hu) 2004-03-01
CN1248683C (zh) 2006-04-05
RU2328283C2 (ru) 2008-07-10
RU2003132687A (ru) 2005-04-10
AU2002244860B2 (en) 2006-11-16
EP1377278A1 (en) 2004-01-07
HK1059213A1 (en) 2004-06-25
ATE344029T1 (de) 2006-11-15
ZA200307156B (en) 2004-06-04
NZ528172A (en) 2004-09-24
DE60215787D1 (de) 2006-12-14
PL366633A1 (en) 2005-02-07
WO2002083109A1 (en) 2002-10-24
NO20034549D0 (no) 2003-10-09
JP2004525179A (ja) 2004-08-19
CA2443229A1 (en) 2002-10-24
CN1501796A (zh) 2004-06-02
CZ20032927A3 (cs) 2004-06-16
UA76452C2 (en) 2006-08-15

Similar Documents

Publication Publication Date Title
HUP0303876A3 (en) Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv
HUP0402107A3 (en) N-substituted pyrrolidin derivatives as dipeptidyl peptidase iv inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0300563A3 (en) Inhibitors of dipeptidyl peptidase iv, pharmaceutical compositions containing them and their use
HUP0102250A3 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
AU2003239302A1 (en) Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
HUS1200030I1 (hu) Dipeptidil peptidáz IV ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás elõállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
TWI350751B (en) Pharmaceutical compositions for treating diabetes
IL182444A0 (en) Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation
EP1583534A4 (en) 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
TWI320406B (en) Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
IL190218A0 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
IL145568A0 (en) Pharmaceutical compositions comprising dipeptidyl peptidase iv inhibitors for the promotion of growth
EP1592689A4 (en) 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OR PREVENTION OF DIABETES
EP1589969A4 (en) 3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2004037181A3 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
EG24124A (en) Pharmaceutical compositions for the treatment of type-II diabetes mellitus
HK1086485A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HK1100559A1 (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
HUP0302770A3 (en) Tripeptidyl peptidase inhibitors, process for their preparation and pharmaceutical compositions containing them
ZA200303037B (en) Herbal pharmaceutical composition for treatment of HIV/Aids patients.
RS98704A (en) New pharmaceutical compositions containing flibanserin polymorpha
WO2002042271A3 (en) Biphenylcarboxamides useful as lipid lowering agents
MXPA05001712A (es) Bifenilcarboxamidas sustituidas con n-aril piperidina como inhibidores de la secrecion de apolipoproteina b.
HUP0401612A3 (en) Pharmaceutical composition suitable for treating diabetes
HUP0400156A3 (en) Pyrrolidine derivatives as factor xa inhibitors, their preparation and pharmaceutical compositions containing them